Literature DB >> 16913846

Despite its strong transactivation domain, transcription factor FOXM1c is kept almost inactive by two different inhibitory domains.

Inken Wierstra1, Jürgen Alves.   

Abstract

FOXM1c (MPP2) is an activating transcription factor with several nuclear localization signals, a forkhead domain for DNA binding, and a very strong acidic transactivation domain. Despite its very strong transactivation domain, FOXM1c is kept almost inactive by two different independent inhibitory domains, the N-terminus and the central domain. The N-terminus as a specific negative-regulatory domain directly binds to and thus inhibits the transactivation domain completely. However, it lacks any transrepression potential. In contrast, the central domain functions as a strong RB-independent transrepression domain and as an RB-recruiting negative-regulatory domain. The N-terminus alone is sufficient to eliminate transactivation, while the central domain alone represses the transactivation domain only partially. This hierarchy of the two inhibitory domains offers the possibility to activate the almost inactive wild type in two steps in vitro: deletion of the N-terminus results in a strong transactivator, while additional deletion of the central domain in a very strong transactivator. We suggest that the very high potential of the transactivation domain has to be tightly controlled by these two inhibitory domains because FOXM1 stimulates proliferation by promoting G1/S transition, as well as G2/M transition, and because deregulation of such potent activators of proliferation can result in tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16913846     DOI: 10.1515/BC.2006.120

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  19 in total

1.  An N-terminal inhibitory domain modulates activity of FoxM1 during cell cycle.

Authors:  H J Park; Z Wang; R H Costa; A Tyner; L F Lau; P Raychaudhuri
Journal:  Oncogene       Date:  2007-09-24       Impact factor: 9.867

2.  The transcription factor FOXM1 is a cellular target of the natural product thiostrepton.

Authors:  Nagaratna S Hegde; Deborah A Sanders; Raphaël Rodriguez; Shankar Balasubramanian
Journal:  Nat Chem       Date:  2011-08-21       Impact factor: 24.427

3.  FOXM1 promotes the warburg effect and pancreatic cancer progression via transactivation of LDHA expression.

Authors:  Jiujie Cui; Min Shi; Dacheng Xie; Daoyan Wei; Zhiliang Jia; Shaojiang Zheng; Yong Gao; Suyun Huang; Keping Xie
Journal:  Clin Cancer Res       Date:  2014-03-14       Impact factor: 12.531

4.  A novel FoxM1-caveolin signaling pathway promotes pancreatic cancer invasion and metastasis.

Authors:  Chen Huang; Zhengjun Qiu; Liwei Wang; Zhihai Peng; Zhiliang Jia; Craig D Logsdon; Xiangdong Le; Daoyan Wei; Suyun Huang; Keping Xie
Journal:  Cancer Res       Date:  2011-12-22       Impact factor: 12.701

5.  A conserved phosphorylation site within the forkhead domain of FoxM1B is required for its activation by cyclin-CDK1.

Authors:  Yi-Ju Chen; Carmen Dominguez-Brauer; Zebin Wang; John M Asara; Robert H Costa; Angela L Tyner; Lester F Lau; Pradip Raychaudhuri
Journal:  J Biol Chem       Date:  2009-09-08       Impact factor: 5.157

6.  Activation of FoxM1 during G2 requires cyclin A/Cdk-dependent relief of autorepression by the FoxM1 N-terminal domain.

Authors:  Jamila Laoukili; Monica Alvarez; Lars A T Meijer; Marie Stahl; Shabaz Mohammed; Livio Kleij; Albert J R Heck; René H Medema
Journal:  Mol Cell Biol       Date:  2008-02-19       Impact factor: 4.272

7.  Anaphase-promoting complex/cyclosome-CDH1-mediated proteolysis of the forkhead box M1 transcription factor is critical for regulated entry into S phase.

Authors:  Hyun Jung Park; Robert H Costa; Lester F Lau; Angela L Tyner; Pradip Raychaudhuri
Journal:  Mol Cell Biol       Date:  2008-06-23       Impact factor: 4.272

8.  Activated FoxM1 attenuates streptozotocin-mediated β-cell death.

Authors:  Maria L Golson; Matthew F Maulis; Jennifer C Dunn; Greg Poffenberger; Jonathan Schug; Klaus H Kaestner; Maureen A Gannon
Journal:  Mol Endocrinol       Date:  2014-07-29

9.  Structure of the FoxM1 DNA-recognition domain bound to a promoter sequence.

Authors:  D R Littler; M Alvarez-Fernández; A Stein; R G Hibbert; T Heidebrecht; P Aloy; R H Medema; A Perrakis
Journal:  Nucleic Acids Res       Date:  2010-03-31       Impact factor: 16.971

10.  FOXM1b, which is present at elevated levels in cancer cells, has a greater transforming potential than FOXM1c.

Authors:  Andy K Y Lam; Adaline W L Ngan; Man-Hong Leung; Davis C T Kwok; Vincent W S Liu; David W Chan; Wai Y Leung; Kwok-Ming Yao
Journal:  Front Oncol       Date:  2013-01-31       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.